A comparison of various methods of measuring antidepressant medication adherence among children and adolescents with major depressive disorder in a 12-week open trial of fluoxetine

Journal of Child and Adolescent Psychopharmacology

Volumn 20, Issue 5, 2010, Pages 431-439

  Nakonezny, Paul A ^a   Hughes, Carroll W ^a   Mayes, Taryn L ^a   Sternweis Yang, Kathryn H ^a   Kennard, Betsy D ^a   Byerly, Matthew J ^a   Emslie, Graham J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; ELECTRONIC MONITORING; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; PATIENT COMPLIANCE; PATIENT MONITORING; PRESCHOOL CHILD; RATING SCALE; SCHOOL CHILD;

ADOLESCENT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CHILD; DEPRESSIVE DISORDER, MAJOR; DRUG MONITORING; FEMALE; FLUOXETINE; HUMANS; MALE; MEDICATION ADHERENCE; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 77958528658     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2009.0108     Document Type: Article

References (33)

1. Benjamini Y, Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Stat Soc 57:289-300, 1995.
2. Birmaher B, Brent D, Bernet W, Bukstein O, Walter H, Benson R, Chrisman A, Farchione T, Greenhill L, Hamilton J, Keable H, Kinlan J, Schoettle U, Stock S, Ptakowski K, Medicus J: Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 46:1503-1526, 2007.
3. Bridge J, Iyengar S, Salary C, Barbe R, Birmaher B, Pincus, H, Ren L, Brent D: Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials. JAMA 297:1683-1696, 2007.
4. Burnier M, Schneider M, Chiolero A, Stubi C, Brunner H: Electronic compliance monitoring in resistant hypertension: The basis for rational therapeutic decisions. J Hypertens 19:335-341, 2001.
5. Byerly M, Fisher R, Whatley K, Holland R, Varghese F, Carmody T, Magouirk B, Rush AJ: A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res 133:129-133, 2005.
6. Byerly M, Nakonezny PA, Lescouflair E: Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am 30:437-452, 2007a.
7. Byerly MJ, Thompson A, Carmody T, Bugno R, Erwin T, Kashner M, Rush AJ: Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psy-chiatr Serv 58:844-847, 2007b.
8. Cramer J, Rosenheck R: Adherence with medication regimens for mental and physical disorders. Psychiatr Serv 49:196-201, 1998.
9. Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J: Medication adherence feedback and monitoring in a clinical trial: Predictions and outcomes. Value Health 6:566-573, 2003.
10. Diaz E, Neuse E, Sullivan MC, Pearsall HR, Woods, SW: Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 65:354-360, 2004.
11. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, Nilsson M, Jacobson, JG: Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 41:1205-1215, 2002.
12. Emslie GJ, Kennard BD, Mayes TL, Nightingale-Teresi J, Carmody T, Hughes CW, Rush AJ, Tao R, Rintelmann JW: Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry 165:459-467, 2008.
13. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, Rintelmann J: A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 54:1031-1037, 1997.
14. Farmer KC: Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 21:1074-1090, 1999.
15. Fotheringham MJ, Sawyer MG: Adherence to recommended medical regimens in childhood and adolescence. J Paediatr Child Health 31:72-78, 1995.
16. Glazer WM, Byerly MJ: Tactics and technologies to manage non-adherence in patients with schizophrenia. Curr Psychiatry Rep 10:359-369, 2008.
17. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988, 1997.
18. Kennard BD, Emslie GJ, Mayes TL, Nightingale-Teresi J, Nakonezny PA, Hughes JL, Jones J M., Tao R, Stewart SM, Jarrett RB: Cognitive-behavioral therapy to prevent relapse in pediatric responders to pharmacotherapy for major depressive disorder. J Am Acad Child Adolesc Psychiatry 47:1395-1404, 2008.
19. Kenward MG, Roger JH: Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 53:983-997, 1997.
20. Lacro J, Dunn L, Dolder C, Leckband S, Jeste D: Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. J Clin Psychiatry 63:892-909, 2002.
21. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, Christian J, Maldonado T, Duran D, Kaplan AH, Wenger NS: A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 134:968-977, 2001.
22. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J: Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA 292:807-820, 2004. (Pubitemid 39079667)
23. Nakonezny PA, Byerly MJ: Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: A comparison of first- vs. second-generation antipsychotics. Schi-zophr Res 82:107-114, 2006.
24. Nakonezny PA, Byerly MJ, Rush AJ: Electronic monitoring of anti-psychotic medication adherence in outpatients with schizophrenia or schizoaffective disorder: An empirical evaluation of its reliability and predictive validity. Psychiatry Res 157:259-263, 2008.
25. Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 353:487-497, 2005.
26. Poznanski E, Mokros H: Children's Depression Rating Scale-Revised (CDRS-R). Los Angeles: WPS; 1996.
27. Riekert KA, Frotar D: The beliefs about medication scale: Development, reliability, and validity. J Clin Psychol Med Settings 9:177-184, 2002.
28. SAS Institute Inc: SAS 9.2 (TS1M0). SAS/STAT. Cary, NC: SAS Institute Inc. 2002, 2008.
29. Tao R, Emslie G, Mayes T, Nakonezny P, Kennard B, Hughes C: Early prediction of acute antidepressant treatment response and remission in pediatric major depressive disorder. J Am Acad Child Adolesc Psychiatry 48:71-78, 2009.
30. Velligan DI, Lam YW, Glahn DC, Barrett JA, Maples NJ, Ereshefsky L, Miller AL: Defining and assessing adherence to oral antipsy-chotics: A review of the literature. Schizophr Bull 32:724-742, 2006.
31. Velligan DI, Wang M, Diamond P, Glahn DC, Castillo D, Bendle S, Lam YW, Ereshefsky L, Miller AL: Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv 58:1187-1192, 2007.
32. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP: The expert consensus guideline series: Adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 70(Suppl 4):1-46, 2009.
33. Wagner GJ, Remien RH, Carballo-Dieguez A, Dolezal C: Correlates of adherence to combination antiretroviral therapy among members of HIV-positive mixed status couples. AIDS Care 14:105-109, 2002.